Tiotropium (Spiriva) Rehabilitation Study
Pulmonary Disease, Chronic Obstructive
About this trial
This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive
Eligibility Criteria
Inclusion Criteria: History of COPD, FEV1 of less than or equal than 60% of predicted normal and less than or equal to 70% at Visit 1, Male or Female 40 years or greater, smoking history of more than 10 pack years (current or ex-smokers), patient can perform all study related tests, patients can inhale medication from HandiHaler and from meter dose inhaler, patients who would benefit from participation in a pulmonary rehab program and patients who had a medical clearance to participate in a pulmonary rehab program. Exclusion Criteria: Patients with significant diseases other than COPD, patients with clinically relevant abnormal baseline hematology, blood chemistry or urinalysis, all patients with SGOT greater than 80IU/L, bilirubin greater than 2.0 mg/dl or creatinine greater than 2.0 mg/dL, recent history of MI (6 months or less). any cardiac arrhythmia requiring drug therapy or has abeen hospitalized for heart failure with the past 3 years, active TB, history of CA or had treatment within the last 24 months, history of CF, bronchiectasis, interstitial lung disease or pulmonary thromboembolic disease.
Sites / Locations
- University of Alabama at Birmingham
- Boehringer Ingelheim Investigational Site
- Attention: John E. Hodgkin, M.D.
- Boehringer Ingelheim Investigational Site
- UCLA School of Medicine
- Boehringer Ingelheim Investigational Site
- Harbor-UCLA Research and Education Institute
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- St. Francis Hospital and Medical Center
- Norwalk Hospital
- Boehringer Ingelheim Investigational Site
- UMass Memorial Medical Center
- Henry Ford Hospital
- University of Nebraska Medical Center
- Duke University Medical Center
- Temple University Hospital
- Boehringer Ingelheim Investigational Site